



US007534803B2

(12) **United States Patent**
Smith et al.

(10) **Patent No.:** **US 7,534,803 B2**
(45) **Date of Patent:** **May 19, 2009**

(54) **METHOD OF TREATING DEMYELINATING DISEASES OR CONDITIONS**

EP 0731108 9/1996
EP 0683165 8/2000
WO WO 96/14066 5/1996
WO WO 01/04091 1/2001

(75) Inventors: **Craig P. Smith**, Hillsborough, NJ (US);
Michel P. Rathbone, Ontario (CA);
Margaret Petty, Bridgewater, NJ (US);
David Rampe, Bernardsville, NJ (US)

OTHER PUBLICATIONS

van Diemen et al., "4-Aminopyridine induces functional improvement in multiple sclerosis patients: A neurophysiological study", *Journal of the Neurological Sciences*, vol. 116, No. 2, pp. 220-226 (1993).*

(73) Assignee: **Aventis Pharmaceuticals Inc.**,
Bridgewater, NJ (US)

Bever, C.T., et al., *The Current Status of Studies of Aminopyridines in Patients with Multiple Sclerosis*, Annals of Neurology, Boston, MA, vol. 36, 1994, pp. S118-S121.

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Tang, L., et al., 4-Aminopyridine Derivatives: A Family of Novel Modulators of Voltage-Dependent Sodium Channels, *Drug Development Research*, vol. 44, No. 1, May 1998, pp. 8-13.

(21) Appl. No.: **11/236,145**

Tang, L., et al., Effects of besipirdine at the voltage-dependent sodium channel, *British Journal of Pharmacology*, vol. 116, No. 5, 1995, pp. 2468-2472.

(22) Filed: **Sep. 27, 2005**

Abou-Gharbia, M., et al., IV Congress of the ECNP, Aggression and anxiety are the first components to respond to antidepressant therapy, *Drug News and Perspectives*, vol. 4, No. 10, Dec. 1, 1991, pp. 647-650.

(65) **Prior Publication Data**

US 2006/0025452 A1 Feb. 2, 2006

Related U.S. Application Data

(62) Division of application No. 10/076,191, filed on Feb. 14, 2002, now Pat. No. 6,967,210.

Villoslada, P., et al., Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System, *Journ. of Experimental Medicine*, vol. 191, No. 10, May 15, 2000, pp. 1799-1806.

(60) Provisional application No. 60/268,846, filed on Feb. 15, 2001.

Eglen, R.M., et al., Muscarinic receptor ligands and their therapeutic potential, *Current Opinion in Chemical Biology*, vol. 3, No. 4, Aug. 1999, pp. 426-432.

(30) **Foreign Application Priority Data**

Aug. 9, 2001 (GB) 0119435.6

Stedman's No title—Stedman's Medical Dictionary, Stedman's Medical Dictionary, 25th Edition, Illustrated, 1994, pp. 391.

(51) **Int. Cl.**
A61K 31/44 (2006.01)

Mysiw, M.J., et al., Medications To Enhance Cognitive Functioning, *Physical Medicine and Rehabilitation Clinics of North America*, 1997, pp. 781-800.

(52) **U.S. Cl.** **514/339**; 514/903

U.S. Appl. No. 11/536,808, filed Sep. 29, 2006, Kongsamut.

(58) **Field of Classification Search** 514/339,
514/903

* cited by examiner

See application file for complete search history.

Primary Examiner—Kevin E Weddington

(74) *Attorney, Agent, or Firm*—Barbara Kurys; Jiang Lin

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,880,822 A * 11/1989 Efland et al. 514/339
4,970,218 A 11/1990 Efland et al.
5,519,131 A 5/1996 Efland et al.
2004/0157888 A1 * 8/2004 Smith et al. 514/339
2004/0157889 A1 * 8/2004 Smith et al. 514/339

FOREIGN PATENT DOCUMENTS

DE 43 25 491 2/1995
EP 0287982 10/1988
EP 0415103 2/1995

(57) **ABSTRACT**

N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.

2 Claims, 11 Drawing Sheets